Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Summit Therapeutics Inc.AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsCompanies: AstraZenecaMIAMI, September 28, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve).
- Building a Leading Occupational Health and Workforce Wellbeing Platform Across North AmericaWEST PERTH, Australia, September 28, 2026--Today marks an important milestone in APM's growth and commitment to helping people live healthier, more productive and independent lives.
- Verastem OncologyVerastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian CancerBOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
- SI-BONE, Inc.SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the PelvisFDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone
- Attovia Therapeutics, Inc.Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.
- Definium Therapeutics, Inc.Definium Therapeutics Announces New Employee Inducement GrantsNEW YORK, September 28, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of Septembe
- Molina Healthcare of MichiganMolina Healthcare of Michigan and The MolinaCares Accord Award $160,000 in Grants to Genesee County-Area Organizations Addressing Social Determinants of HealthCompanies: Molina HealthcareFLINT, Mich., September 28, 2026--Molina Healthcare of Michigan & The MolinaCares Accord Award $160,000 in grants to Genesee County organizations Addressing SDOH.
- MedcorMedcor to Join the APM Group, Expanding Occupational Health Services Across North AmericaMCHENRY, Ill., September 28, 2026--Medcor, a leading provider of onsite and mobile occupational health services across the United States and Canada, today announced it has entered into an agreement to join the APM Group, subject to Federal Trade Commission approval. Medcor and APM, an international health and human services organization operating in 11 countries, will work together to expand access for employers and their employees to high-quality, independent, advocacy-based occupational health
- CochlearCochlear Reaches More Than 1 Million Hours of Patient Experience Across Its Fully Implantable Hearing Technology Research ProgramSYDNEY, September 28, 2026--Cochlear today announced the completion of recruitment for the worldwide pivotal trial program evaluating fully implantable hearing technology. Patients across Cochlear’s fully implantable hearing system research programs have experienced more than 1 million hours with their device to date.
- Meitheal Pharmaceuticals, Inc.Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®CHICAGO, September 28, 2026--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced that the U.S. Food and Drug Administration ("FDA") has approved a high-concentration formulation ("HCF") for YUSIMRY® (adalimumab-aqvh), as an interchangeable biosimilar to Humira®.
- Fetal surgeon Payam Saadai, MD, to join Rady Children’s Health Orange CountyPayam Saadai, MD, FACS, FAAP, will join Rady Children's Health OC's Fetal Care Center of Southern California as a fetal surgeon.
- Eden RadioisotopesEDEN RADIOISOTOPES ADVANCES $1.4 BILLION NEW MEXICO MEDICAL ISOTOPE PROJECTState support, selection of Kiewit Nuclear Solutions Co. and continued partnership with Sargent & Lundy mark major steps toward development of first-of-its-kind U.S. medical isotope production facility ALBUQUERQUE, N.M., Sept. 28, 2026 -- Eden Radioisotopes today announced...